The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes
- 1 November 2005
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (11), 2686-2690
- https://doi.org/10.2337/diacare.28.11.2686
Abstract
OBJECTIVE—Ruboxistaurin selectively inhibits protein kinase C-β and ameliorates kidney disease in animal models of diabetes. The purpose of this study was to evaluate the effects of ruboxistaurin on diabetic nephropathy in humans. RESEARCH DESIGN AND METHODS—A randomized, double-blind, placebo-controlled, multicenter, pilot study was performed to evaluate the effects of 32 mg/day ruboxistaurin for 1 year in persons (n = 123) with type 2 diabetes and persistent albuminuria (albumin-to-creatinine ratio [ACR] 200-2,000 mg/g), despite therapy with renin-angiotensin system inhibitors. The primary end point was a change in the ACR. Estimated glomerular filtration rate (eGFR) (four-component equation from the Modification of Diet in Renal Disease study) was also calculated. RESULTS—At baseline, urinary ACR was 764 ± 427 mg/g (means ± SD), and eGFR was 70 ± 24 ml/min per 1.73 m2. Systolic and diastolic blood pressures were 135 ± 14 and 75 ± 9 mmHg, respectively. HbA1c was 8.0 ± 1.2%. After 1 year, urinary ACR decreased significantly (−24 ± 9%) in participants treated with ruboxistaurin (P = 0.020) and nonsignificantly (−9 ± 11%) in the placebo group (P = 0.430). The ACR-lowering effect of ruboxistaurin appeared by 1 month. eGFR did not decline significantly in the ruboxistaurin group (−2.5 ± 1.9 ml/min per 1.73 m2) (P = 0.185), whereas the placebo group lost significant eGFR over 1 year (−4.8 ± 1.8 ml/min per 1.73 m2) (P = 0.009). Between-group differences for changes in ACR and eGFR were not statistically significant, but this pilot study was underpowered to determine such differences. CONCLUSIONS—In persons with type 2 diabetes and nephropathy, treatment with ruboxistaurin reduced albuminuria and maintained eGFR over 1 year. Ruboxistaurin may add benefit to established therapies for diabetic nephropathy.Keywords
This publication has 20 references indexed in Scilit:
- USRDS 2004 annual data reportAmerican Journal of Kidney Diseases, 2005
- Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2004
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With NephropathyCirculation, 2004
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C β inhibitionAmerican Journal of Kidney Diseases, 2003
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2003
- Effect of dietary protein restriction on prognosis in patients with diabetic nephropathyKidney International, 2002
- Standards of Medical Care for Patients With Diabetes MellitusDiabetes Care, 2002
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2001
- Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β InhibitorScience, 1996